Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety, tolerability, and pharmacokinetics of multiple doses of VAK694 in adults with allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• VAK694

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Allergic Rhinitis | Phase 2 | Status: COMPLETED